

25 July 2018

Scancell Holdings plc
(“Scancell” or the “Company”)

PDMR Dealing

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer announces the following director share sale and re-purchase transaction, undertaken to satisfy a charge in relation to a SIPP.

On 24 July 2018, Dr John Chiplin sold 2,483 ordinary shares at 11 pence per ordinary share and on 25 July 2018, Dr John Chiplin purchased 2,483 ordinary shares at 11.7 pence per ordinary share. Following the transaction, Dr John Chiplin’s total interest of 2,000,000 remains unchanged, representing 0.52% of the total voting rights.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Dr John Chiplin
2	Reason for the notification	
a)	Position/status	Chairman and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Sale of Ordinary Shares
d)	Price(s) and volume(s)	2,483 Ordinary Shares 11 pence per Ordinary Share
e)	Aggregated information - Aggregated volume - Price	2,483 Ordinary Shares 11 pence per Ordinary Share
f)	Date of the transaction	24 July 2018
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Dr John Chiplin
2	Reason for the notification	
a)	Position/status	Chairman and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	2,483 Ordinary Shares 11.7 pence per Ordinary Share
e)	Aggregated information - Aggregated volume - Price	 2,483 Ordinary Shares 11.7 pence per Ordinary Share
f)	Date of the transaction	25 July 2018
g)	Place of the transaction	London Stock Exchange, AIM

- ENDS -

For more information, please contact:

Dr John Chiplin, Chairman	Scancell Holdings plc	+44 (0) 20 3727 1000
Dr Cliff Holloway, CEO		

Freddy Crossley/Emma Earl/Ryan McCarthy	Panmure Gordon	+44 (0) 20 7886 2500
---	----------------	----------------------

Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000
------------------------	----------------	----------------------

Notes for Editors

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat of a wide variety of cancers.

- Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.

For further details, please see our website: www.scancell.co.uk